Results · Apr-Jun 2026
Indrayani Biotech Q1 FY27 results
Sales grew 30% to ₹37.7 crore from ₹29.1 crore in Apr-Jun 2025.
Operating profit fell 33% to ₹1.5 crore, an operating margin of 3.9% (down 3.6 points from a year ago).
Net profit grew 245% to ₹0.54 crore from ₹0.16 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −0%, net profit −45%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 37.7 | 29.1 | +30% |
| Operating profit (EBITDA) | 1.5 | 2.2 | −33% |
| Operating margin | 3.9% | 7.5% | −3.6 pts |
| Net profit | 0.5 | 0.2 | +245% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.